Editorial Staff

Clinical Editor
Morton Kern, MD
Executive Editor
Laurie Gustafson
Managing Editor
Rebecca Kapur
Production Manager
Elizabeth Vasil

Editorial Correspondence

Rebecca Kapur, Managing Editor, Cath Lab Digest
HMP Communications, 70 E. Swedesford Rd
Suite 100, Malvern PA 19355
Telephone: (440) 717-0418

Fax: (866) 896-8762
Email: rkapur@hmpglobal.com

October 2018

|
Volume 26 Issue 10
The following summary provides a high-level look at the upcoming fiscal year (FY) 2019 changes in terms of financial and quality standards.
This is a single-center prospective review of a database of patients who underwent endovascular intervention of their PAD with an attempted pedal-first approach by a single operator.
Our case illustrates a rare complication of an aorto-RV fistula that did not require repair.
“This real-world evidence shows an unprecedented increase in survival outcomes for AMI cardiogenic shock patients and is a result of the increased adoption of best practices for treating cardiogenic shock,” said Dr. O’Neill.
The FDA’s approval is based on findings from the IMPERIAL trial, in which the Eluvia stent demonstrated superior results in the first superficial femoral artery head-to-head drug-eluting stent trial.
The COAPT trial met both the primary safety and efficacy endpoints and all secondary endpoints, including reducing all-cause mortality through two years.